Geopolitics Alpha

Market closed · last trade · ETF proxies, Alpaca IEX

FDA finalizes guidance on transferring 510(k) ownership

Published . Updated .

Key takeaways

  • The US Food and Drug Administration (FDA) has finalized a guidance that outlines the responsibilities of owners of 510(k) clearances when products are sold or transferred between companies.
  • Exposed: XLV, XBI, LLY, JNJ, PFE
  • Market reaction: price tracking starts with the next trading session.

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest and never sell or share it. See our privacy policy.

FDA finalizes guidance on transferring 510(k) ownership

The US Food and Drug Administration (FDA) has finalized a guidance that outlines the responsibilities of owners of 510(k) clearances when products are sold or transferred between companies. The final document significantly shortens certain sections, while adding new questions

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.

  • XBI SPDR S&P Biotech ETF

    SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.

  • LLY Eli Lilly and+25.1% 30d

    Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.

  • JNJ Johnson & Johnson+12.1% 30d

    Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.

  • PFE Pfizer+5.2% 30d

    Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.

  • MRK Merck+3.5% 30d

    Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
XLV+6.43%+4.39%baseafter closeafter closeafter closeafter close
XBI+3.94%+0.30%baseafter closeafter closeafter closeafter close
LLY+6.85%+4.70%baseafter closeafter closeafter closeafter close
JNJ+7.03%+4.32%baseafter closeafter closeafter closeafter close
PFE+4.75%+3.15%baseafter closeafter closeafter closeafter close
MRK+11.08%+7.78%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

FDA finalizes guidance on transferring 510(k) ownership RAPS

Source: RAPS

Select Sector Spdr Tr (XLV) since “FDA finalizes guidance on transferring 510(k) ownership,” compared with the market

CompanyWhenMoveStatus
Johnson & Johnson (JNJ)three days earlier+4.32%final price
Johnson & Johnson (JNJ)five days earlier+7.03%final price
Eli Lilly (LLY)three days earlier+4.70%final price
Eli Lilly (LLY)five days earlier+6.85%final price
Merck (MRK)three days earlier+7.78%final price
Merck (MRK)five days earlier+11.08%final price
Pfizer (PFE)three days earlier+3.15%final price
Pfizer (PFE)five days earlier+4.75%final price
Spdr Series Trust (XBI)three days earlier+0.30%final price
Spdr Series Trust (XBI)five days earlier+3.94%final price
Select Sector Spdr Tr (XLV)three days earlier+4.39%final price
Select Sector Spdr Tr (XLV)five days earlier+6.43%final price

Trades by members of Congress and officials in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Select Sector Spdr Tr (XLV)

Companies carried with this story

  • XLV Select Sector Spdr Tr

    For “FDA finalizes guidance on transferring 510(k) ownership,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story

  • XBI Spdr Series Trust

    Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 19 Nov 2026 story “FDA finalizes guidance on transferring 510(k) ownership.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story

  • LLY Eli Lilly

    Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 19 Nov 2026 story “FDA finalizes guidance on transferring 510(k) ownership.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story

  • JNJ Johnson & Johnson

    In “FDA finalizes guidance on transferring 510(k) ownership,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story

  • PFE Pfizer

    In “FDA finalizes guidance on transferring 510(k) ownership,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story

  • MRK Merck

    In “FDA finalizes guidance on transferring 510(k) ownership,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story

How “FDA finalizes guidance on transferring 510(k) ownership” reaches Select Sector Spdr Tr (XLV)

“FDA finalizes guidance on transferring 510(k) ownership” (19 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.

For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story

Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story

Dates and price levels for Select Sector Spdr Tr (XLV)

LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.

How solid “FDA finalizes guidance on transferring 510(k) ownership” looks

46 out of 100

“FDA finalizes guidance on transferring 510(k) ownership” scores 46 out of 100. The score uses 1 source, and 6 linked companies.